Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | HTT | P42858 | 5/20 | 0.81 |
| ▸ | POLB | P06746 | 4/20 | 0.81 |
| ▸ | DDX3X | O00571 | 2/20 | 0.81 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | BAZ1A | Q9NRL2 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047211 | 0.90 | MEN1 (1.00) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL17084065 | 0.88 | MEN1 (0.96) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL6129390 | 0.85 | MEN1 (0.90) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL14336428 | 0.84 | KMT2A (0.81) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL1694713 | 0.81 | KMT2A (0.77) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL1694714 | 0.81 | KMT2A (0.77) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL29494959 | 0.81 | MAPT (0.82) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL10069069 | 0.81 | KMT2A (0.82) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL29494984 | 0.81 | MEN1 (0.82) | MEN1KMT2AMAPTHTTPOLB | |
| SCHEMBL22092648 | 0.81 | MAPT (0.82) | MEN1KMT2AMAPTHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098467-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20100240646-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| US-7759343-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7642257-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| US-7419978-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-10 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | MEN1 2635/4885KMT2A 718/4885MAPT 1958/4885 |
| US-20110098467-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | PLK2, CDK2, MAP3K15 | MEN1 2635/4885KMT2A 718/4885MAPT 1958/4885 |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | PLK2, CDK2, MAP3K15 | MEN1 2635/4885KMT2A 718/4885MAPT 1958/4885 |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | MEN1 2648/4885KMT2A 391/4885MAPT 2263/4885 |
| US-20100240646-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | PLK2, CDK2, MAP3K15 | MEN1 2635/4885KMT2A 718/4885MAPT 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.